The aim of this prospective study was to evaluate left atrial (LA) function for the prediction of increased risk of newonset non-valvular atrial fibrillation (AF). Risk stratification for new-onset AF based on LA remodelling may have a major public health impact. Although left atrial volume (LAV) or LA dimension have been proposed as predictors of AF, other predictive parameters of LA function have not yet been fully examined.
detect patients at increased risk of new-onset AF. The aim of the present study was to elucidate parameters of LA function measured by VVI to predict new-onset AF.
Methods

Subjects and study protocol
This was a prospective study that elucidated parameters for the prediction of new-onset AF. From August 2008 until January 2009, 792 consecutive adults ≥20 years of age were studied by the transthoracic echocardiography in our echocardiography laboratory. We performed echocardiography to screen for cardiac disease in subjects with chest pain, chest discomfort, palpitations, cardiac murmurs, or ECGdocumented arrhythmias. We also performed echocardiography to evaluate the severity of disease in patients that were previously diagnosed with hypertension, valvular heart disease, or coronary artery disease. Inclusion criteria were patients who needed medications for condition such as hypertension, type 2 diabetes mellitus, dislipidaemia, coronary artery disease, mild mitral regurgitation or other valvular heart disease, heart failure or arrhythmias other than atrial arrhythmias, patients with ECG abnormalities such as non-specific ST-T change, bundle blanch block, or first-or second-degree atrioventricular block that did not require specific medication. Exclusion criteria were subjects without disease, patients with mitral stenosis, moderate to severe mitral regurgitation, previous mitral valve surgery, permanent cardiac pacemaker implantation, and atrial arrhythmias such as AF, atrial flutter, or atrial tachycardia documented by ECG or Holter ECG. In addition, 12 subjects were excluded from the study because of poor echocardiographic recordings due to severe obesity or emphysema. The final study population consisted of 580 subjects that were followed up for the development of new-onset AF. Risk factors for coronary artery disease were evaluated in each patient, including hypertension (medication-dependent only), diabetes mellitus type 2 (medication-dependent only), dyslipidaemia (medicationdependent only), and current smoking. Medical therapy was also evaluated in each patient. We performed monthly ECG examinations in all enrolled subjects regardless of symptoms of arrhythmia during the follow-up period. All subjects who had palpitations and/or symptoms of arrhythmia underwent both ECG and Holter ECG examination to confirm the development of new-onset AF. All AF was finally confirmed by Holter ECG examination. We defined the time point of development of AF as the month when Holter ECG examination confirmed the presence of AF. The present study was approved by the Ethics Committee of our institution and informed consent was obtained from all patients before enrolment.
Echocardiography
Transthoracic echocardiography was performed using an ACUSON sequoia 512 (Siemens, Mountain View, CA, USA) ultrasound system with ultrasound transducer at 4V1c (1.5-4.25 MHz) to evaluate LA function. LA volumes were measured during a single cardiac cycle by VVI with feature-tracking echocardiography using on-line software (Syngo Velocity Vector Imaging, Siemens). The reliability of the featuretracking echocardiographic method for the quantification of LA function has been established in previous studies. 4 With this method, the endocardial border of LA is visually identified and manually outlined by the examiner. Manual placement of an endocardial tracing over one frame is then automatically tracked throughout the cardiac cycle. The software allows editing of the initial trace and the endocardial velocity is derived as the ratio between frame to frame displacement and the time interval, 5 The velocity vectors in the two dimensional plane are displayed throughout the cardiac cycle, representing displacement of the speckles in relation to each other along the endocardial contour of the LA. VVI is an endocardial border tracking technique, Therefore, VVI can track the movement of a thin-walled structure such as the LA. Then, a time -LA volume curve and strain rate (SR) can be automatically and promptly provided ( Figure 1A and B). Maximum LAV, minimum LAV, and LAV just before atrial contraction were obtained from the apical four-chamber view by VVI with a frame rate of 55 -60 frames/s using Simpson's method ( Figure 1C and  D) . LA total emptying function (EF) (reservoir function), passive EF (conduit function), and active EF (booster pump function) were calculated to evaluate phasic LA function. LA total, passive, and active EF were defined as (maximum LAV 2 minimum LAV)/maximum LAV × 100%, (maximum LAV -pre-atrial contraction LAV)/maximum LAV × 100% and (pre-atrial contraction LAV 2 minimum LAV)/ pre-atrial contraction LAV × 100% during a cardiac cycle ( Figure 2) . LA peak SR during systole, early diastole and atrial contraction were also obtained from the LA mid-septal and mid-lateral walls to evaluate phasic LA function. Average values of SR from the mid-septal and midlateral walls were used for the analysis. Moreover, LA peak strain was obtained from the average of LA mid-septal and mid-lateral wall strain. Several conventional echocardiographic parameters were measured according to standard echocardiographic methods. 6 The LV ejection fraction as a traditional index of LV systolic function, LA dimension and LV mass, and the ratio of early diastolic transmitral inflow velocity to annular tissue velocity (E/e ′ ) as an index of diastolic function were measured. Maximum LAV index, pre-atrial contraction LAV index and minimum LAV index were calculated as maximum LAV divided by body surface area, pre-atrial contraction LAV divided by body surface area and minimum LAV divided by body surface area, respectively.
Reliability and reproducibility of left atrial volume and left artrial ejection fraction by velocity vector imaging method In 20 patients, the values measured by VVI were compared with the values measured by enhanced computed tomography (CT) in a blinded manner to validate the VVI measurement. CT imaging was performed with a 64-slice CT scanner (Aquilion TSX-101A 64 rows, Toshiba Medical Systems, Tokyo, Japan). Radiographic contrast (100 mL of Iopamidol, iodine 370 mg/mL, Schering) was injected intravenously at a flow rate of 3 -5 mL/s (0.07 mL/kg/s) when there was 50 HU in the descending aorta, followed by 20 mL of a saline solution chaser bolus. Image reconstruction was performed by a computer that was part of the CT system, and LAV was automatically calculated by the software (Virtual Press, AZE, Tokyo, Japan). The effective slice thickness was 0.5 mm.
Maximum LAV, minimum LAV, and LA total EF measured by VVI were compared with the values obtained by the manual tracing method in 66 randomly selected patients. We also determined the inter-observer variability of maximum LAV, minimum LAV, and LA total EF in 66 randomly selected recordings that were measured by two observers using VVI in a blinded manner. Likewise, we determined the intra-observer variability of maximum LAV, minimum LAV, and LA total EF in 66 randomly selected recordings that were measured twice by one observer at 7-day interval using VVI.
Statistical analyses
The data are expressed as the mean + one standard deviation. The relationship between the VVI method and the manual tracing method or enhanced CT in maximum LAV, minimum LAV, and LA total EF were tested by linear regression analysis. Categorical data were summarized as percentages and compared with a x 2 test. Echocardiographic parameters between the AF and non-AF groups were compared by an unpaired Student's t-test. The optimal cut-off values for determination of the sensitivity and specificity for first AF in echocardiographic parameters were obtained from receiver operating characteristic (ROC) curve analysis. Multivariate logistic regression analysis was performed to identify the independent predictors of new-onset AF. We performed multivariate analysis using three models. Model 1 included only clinical parameters with a P-value , 0.05 in the singlevariate analysis. Model 2 included clinical and conventional echocardiographic parameters. Model 3 included clinical, conventional, and VVI echocardiographic parameters. A P-value , 0.05 was considered to be significant.
Results
Reproducibility and reliability of left atrial volume and left artrial ejection fraction by velocity vector imaging method
The inter-observer correlation coefficient and relative differences in maximum LAV, minimum LAV, and LA total EF measured by the VVI method were 0.98 and 0.94 + 6.8%, 0.99 and 8.0 + 11.0%, and 0.99 and 2.2 + 15.9%, respectively. The intra-observer correlation coefficient and relative differences in maximum LAV, minimum LAV, and LA total EF by the VVI method were 0.98 
Validation of velocity vector imaging method by computed tomography
There were significant correlations between the VVI method and enhanced CT for the evaluation of maximum LAV (r ¼ 0.95, P , 0.001), minimum LAV (r ¼ 0.96, P , 0.001), and LA total EF (r ¼ 0.97, P , 0.001) ( Figure 3 ).
Patient characteristics
The patients' clinical characteristics at baseline are listed in Table 1 . During a follow-up period of 28 months (median: 28 months, 25 percentile: 26 months, 75 percentile: 30 months), 32 of 580 (5.5%) subjects developed electrocardiographically confirmed new-onset AF. The AF group was significantly older than the non-AF group. There were no significant differences between the two groups in the history of diabetes mellitus, history of dyslipidaemia, current smoking, and concomitant medication use except for calcium channel blockers. There were also no significant differences between the two groups in antiarrhythmic medications because patients with atrial tachyarrhythmias documented by ECG or Holter ECG were excluded. The frequency of hypertension and coronary artery disease was significantly higher in the AF group than in the non-AF group.
Echocardiographic parameters
The time -LA volume curve was easily and quickly obtained in all 580 subjects (Figure 1 ). There was a strong correlation between the VVI and manual tracing methods for the maximum LAV, minimum LAV, and LA total EF (r ¼ 0.98, r ¼ 0.98, r ¼ 0.95, respectively, all P , 0.001). LV diastolic function (E/e ′ ), LV mass, LAD, and LAV index were significantly increased in the AF group compared with the non-AF group, despite no difference in LV systolic function. LA phasic function was significantly reduced in the AF group compared with the non-AF group ( Table 1) . Echocardiographic parameters with a P-value , 0.001 and clinical parameters with a P-value , 0.05 in an unpaired Student's t-test and x 2 test
were included in multivariate logistic regression analysis. However, minimum LAV index was excluded because there was a strong correlation between maximum LAV index and minimum LAV index (r ¼ 0.95, P , 0.001). In multivariate logistic regression analysis, LA active EF was the only independent predictors of newonset AF ( Table 2 ). The sensitivity, specificity, and accuracy for AF prediction at the optimal cut-off values based on ROC curve analysis are listed in Table 3 and shown in Figure 4 . A Kaplan -Meier curve shows the difference in AF-free survival after the baseline measurements in the subjects stratified by LA active EF (≤20 vs. .20%) ( Figure 5 ).
Discussion
We examined LA structure and function in 580 adults, who were prospectively followed for the development of new-onset AF, and demonstrated that LA active EF (booster pump function) as assessed by VVI was decreased in the AF group compared with the non-AF group. We also demonstrated that reduced LA active EF (≤20%) assessed by VVI was the most useful predictor for new-onset AF with a sensitivity of 88% and a specificity of 81%.
Echocardiographic predictors of atrial fibrillation
LA structural and functional remodelling is caused by stressors to the LA. Development of LV diastolic dysfunction with ageing 7 is initially accompanied by a progressive abnormality in LV filling. 8, 9 LA enlargement as determined by conventional echocardiography has been proposed as a predictor of AF. 10 -12 There have been a few studies that used LA function to predict AF. 13, 14 A previous prospective study demonstrated that minimum LA volume was an independent predictor of new-onset AF or atrial flutter. 12 However, the predictive ability of minimum LA volume was only moderate (area under the ROC curve ¼ 0.65-0.69). Abhayaratna et al. 13 pump function) but not LA total EF (reservoir function) was an independent predictor of new-onset AF (area under the ROC curve ¼ 0.92). Furthermore, LA active EF (booster pump function) was a much better predictor of new-onset AF than LA dimension or LAV index. We previously reported an increase in pathological degeneration of the LA wall using integrated backscatter values measured by transesophageal echocardiography, and the degeneration in the LA wall was more advanced in subjects with than without paroxysmal AF; however, LA diameter was similar between the subjects with and without paroxysmal AF. 15 Taken together, the results of these two studies suggest that LA booster pump function might be associated with LA degeneration.
Booster pump function as a predictor of atrial fibrillation
The LA is a contractile chamber that actively empties immediately before the onset of LV systole and affects the final LV end-diastolic volume. 16 LA booster pump function assessed by LA active EF or SR during atrial contraction represents intrinsic LA contractility in which LA myocytes use adenosine triphosphate to actively contract. In contrast, LA reservoir function assessed by LA total EF or SR during systole may represent intrinsic LA relaxation, but it is in part affected by LV systolic performance. 17 Thus, LA booster pump function assessed by LA EF or SR might be the most important and sensitive predictor of new-onset AF since this parameter reflects the loading conditions of the LA. A previous transthoracic echocardiography study demonstrated that total and active EF in PAF were impaired in comparison with the subjects with sinus rhythm. 18 Another study demonstrated that the occurrence of PAF in hypertensive patients was associated with enhanced LA reservoir and conduit function and worse booster pump function. 19 Doppler intracardiac echocardiography study showed that preserved LA booster pump function during AF is predictive of satisfactory recovery of booster pump function after successful pulmonary venous isolation. 20 The results in the present study reinforced the results in the previous studies. LA structural remodelling is often accompanied by a change in LA function with progressive increase in interstitial fibrosis. 3 LA remodelling is accelerated in disease processes, such as hypertension, diabetes mellitus, hyperlipidaemia, ischaemic heart disease, and obesity. shift is an adaptation to chronic overload that maximizes atrial work at the expense of contraction velocity. 21 The results of our study suggest that the reduction in LA booster pump function may be a manifestation of LA mechanical remodelling leading to the development of new-onset AF.
Clinical implications
Although guidelines for the management of patients with AF were established by the committee of the ESC, ACC, and AHA, thromboembolic events related to AF result in significant morbidity and mortality. 16 -18,22 It is common knowledge that anticoagulant therapy can reduce thromboembolic risk in patients with AF. However, a large proportion of AF patients will not develop thromboembolism, but these patients will be exposed to the risks of warfarin therapy. 23 Therefore, delay or prevention of AF is the ultimate goal in the clinical setting. Improved risk stratification is crucially needed to improve the prediction of AF. Previous studies have reported that treatment with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers can delay the progression of paroxysmal AF to chronic AF. 24 -26 The findings of the present study suggest that it might be possible to delay or prevent new-onset AF by detecting the patients with reduced LA active EF and initiating treatment with those drugs.
Study limitations
There are several limitations of the present study. First, the number of incident AF cases may have been underestimated because some patients with AF had no symptoms and the only AF episodes that were confirmed by Holter ECG were considered an endpoint. Second, the positive predictive value (21%) of active EF for new-onset AF was low because the overall incidence of AF in our study population of primary prevention was low (5.5%/ 2.4 years). Combining other parameters with atrial function may be needed to improve the positive predictive value for AF. Finally, VVI is based on manual tracing and represents a two-dimensional measurement. Three-dimensional speckle tracking echocardiography is the latest technique and is now available to assess LA structure and function, including LA volume and strain without any assumptions of LA geometry. 27 Reassessment of predictive values and cut-offs in the present study by three-dimensional speckle tracking echocardiography is needed in the future.
Conclusion
This prospective study demonstrated that baseline LA function assessed in sinus rhythm was reduced in patients that developed new-onset AF compared with the non-AF group. The predictive value of LA function was independent of LA size, suggesting that LA functional remodelling occurred prior to the first episode of AF. Non-invasive echocardiographic assessment of LA phasic function by VVI while in sinus rhythm, particularly LA active contraction (booster pump function), may provide incremental value for risk stratification and be a more useful predictor than LA size for new-onset AF.
